Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax

Area of Science:

• Oncology
• Preclinical Cancer Models
• Biotechnology

Background:

• Bcl-2 family inhibitors show promise in hematologic malignancies.
• Existing preclinical models struggle to replicate systemic disease progression and longitudinal analysis.
• Need for improved models to assess drug efficacy in bone marrow and central nervous system compartments.

Purpose of the Study:

• To develop and validate novel bioluminescent preclinical models for evaluating Bcl-2 family inhibitors.
• To enable longitudinal monitoring of systemic tumor engraftment and response to therapy.
• To better reflect clinical responses observed in patients with hematologic cancers.

Main Methods:

• Intravenous inoculation of engineered RS4;11 (ALL) and Granta 519 (MCL) bioluminescent reporter cell lines.
• Establishment of bone marrow engraftment and central nervous system invasion models.
• Longitudinal monitoring of tumor burden and apoptosis induction using optical imaging.
• Assessment of response to Bcl-2 family inhibitors and standard-of-care agents.

Main Results:

• Successful engraftment of bone marrow by engineered leukemia and lymphoma cell lines.
• Demonstrated central nervous system invasion with Granta 519 cells.
• Optical imaging allowed real-time tracking of apoptosis and tumor response to inhibitors.
• Preclinical model responses correlated more accurately with observed clinical outcomes.

Conclusions:

• Bioluminescent reporter cell lines provide a robust platform for preclinical evaluation of Bcl-2 inhibitors in hematologic malignancies.
• These models facilitate longitudinal assessment of systemic disease and therapeutic efficacy.
• The developed models offer a more accurate preclinical reflection of clinical responses, aiding drug development.